Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Treatment De-Intensification and Residual HIV-1 in Youth

NCT00867854 · View on ClinicalTrials.gov ↗

Study Summary

This laboratory-based sub-study of ATN 061 and ATN 071 will examine the effect of early treatment followed by treatment de-intensification to atazanavir/ritonavir (ATV/r) monotherapy on steady-state frequencies of replication-competent CD4+ T cell Human Immunodeficiency Virus (HIV)-1 reservoirs or cell-associated infectivity (CAI) and persistent low-level viremia (LLV), and their contribution to successful long-term control of HIV-1 replication among HIV-1 infected adolescents and young adults.

Conditions Studied

Interventions

  • OTHER Blood draw

Study Locations (17)

Florida

  • Children's Diagnostic and Teatment Center — Fort Lauderdale
  • University of Miami School of Medicine — Miami
  • University of South Florida College of Medicine — Tampa

California

  • Children's Hospital of Los Angeles — Los Angeles
  • University of California at San Francisco — San Francisco

District of Columbia

  • Children's National Medical Center — Washington D.C.
  • Howard University - IMPAACT Site — Washington D.C.

Illinois

  • John Stroger Jr. Hospital of Cook County — Chicago
  • Children's Memorial Hospital — Chicago

Maryland

  • University of Maryland — Baltimore
  • Johns Hopkins University - IMPAACT Site — Baltimore

New York

  • Mount Sinai Medical Center — New York
  • Montefiore Medical Center — The Bronx

Louisiana

  • Tulane Medical Center — New Orleans

Pennsylvania

  • Children's Hospital of Philadelphia — Philadelphia

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2009-02
Est. Completion 2011-10

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00867854

The ClinicalTrials.gov registry entry for NCT00867854 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 725 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention — of which Blood draw is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00867854 reports 17 study locations spanning 10 distinct geographic areas — top geographies include Florida, California, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00867854 about?

NCT00867854 is a clinical study titled "Treatment De-Intensification and Residual HIV-1 in Youth". This laboratory-based sub-study of ATN 061 and ATN 071 will examine the effect of early treatment followed by treatment de-intensification to atazanavir/ritonavir (ATV/r) monotherapy on steady-state frequencies of replication-competent CD4+ T cell Human Immunodeficiency Virus (HIV)-1 reservoirs or c...

What is the current status of trial NCT00867854?

This trial is currently completed. The enrollment target is 34 participants. The study started on 2009-02. Estimated completion is 2011-10.

What conditions does trial NCT00867854 study?

This clinical trial studies the following conditions: HIV Infections, HIV-1. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00867854?

The interventions under investigation include: Blood draw (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00867854?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 725 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00867854 being conducted?

This trial has 17 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial